

Faramarz Ismail-Beigi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2947670/faramarz-ismail-beigi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

2,087
citations

17
h-index

45
g-index

48
ext. papers

2,558
ext. citations

6.8
avg. IF

4.76
L-index

#	Paper	IF	Citations
44	Peptide Model of the Mutant Proinsulin Syndrome. I. Design and Clinical Correlation.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 821069	5.7	2
43	Association of glycemia with insulin sensitivity and β cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107912	3.2	2
42	Study rationale and design of a study of EMPagliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 318	2.3	1
41	Association of Baseline Characteristics With Insulin Sensitivity and β Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021 , 44, 340-349	14.6	3
40	Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Diabetes Therapy</i> , 2021 , 12, 843-861	3.6	18
39	Evolution of insulin at the edge of foldability and its medical implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 29618-29628	11.5	18
38	Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 113	2.3	5
37	"Register-shift" insulin analogs uncover constraints of proteotoxicity in protein evolution. <i>Journal of Biological Chemistry</i> , 2020 , 295, 3080-3098	5.4	6
36	Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin. <i>Diabetes</i> , 2020 , 69, 1815-1826	0.9	6
35	Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. <i>Advances in Therapy</i> , 2020 , 37, 3450-3462	4.1	5
34	Reassessment of an Innovative Insulin Analogue Excludes Protracted Action yet Highlights the Distinction between External and Internal Diselenide Bridges. <i>Chemistry - A European Journal</i> , 2020 , 26, 4695-4700	4.8	4
33	Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Advances in Therapy</i> , 2020 , 37, 4697-4708	4.1	26
32	Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 246-252	2.1	5
31	Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018). <i>Primary Care Diabetes</i> , 2020 , 14, 222-231	2.4	6
30	Glucocorticoid-Induced Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 1133-1145	3.4	25
29	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 682-690	8.1	2
28	Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4949-4966	5.6	10

27	A View Beyond HbA1c: Role of Continuous Glucose Monitoring. <i>Diabetes Therapy</i> , 2019 , 10, 853-863	3.6	60
26	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 1001-1012	3.4	15
25	Prolonged Exposure to Insulin Inactivates Akt and Erk and Increases Pancreatic Islet and INS1E -Cell Apoptosis. <i>Journal of the Endocrine Society</i> , 2019 , 3, 69-90	0.4	8
24	Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding. <i>Journal of Biological Chemistry</i> , 2018 , 293, 69-88	5.4	8
23	An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein. <i>Journal of Biological Chemistry</i> , 2018 , 293, 47-68	5.4	17
22	Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1181-1189	3.9	7
21	Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016). <i>Scientific Reports</i> , 2017 , 7, 13461	4.9	125
20	Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1343-52	6.9	59
19	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015 , 38, 2000-8	14.6	26
18	Aromatic anchor at an invariant hormone-receptor interface: function of insulin residue B24 with application to protein design. <i>Journal of Biological Chemistry</i> , 2014 , 289, 34709-27	5.4	20
17	Protective hinge in insulin opens to enable its receptor engagement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E3395-404	11.5	106
16	The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. <i>Ophthalmology</i> , 2014 , 121, 2443-51	7.3	164
15	Risk of insulin accumulation (stacking) with use of novel ultralong-acting insulin formulations. <i>Endocrine Practice</i> , 2014 , 20, 990-1	3.2	
14	Biophysical optimization of a therapeutic protein by nonstandard mutagenesis: studies of an iodo-insulin derivative. <i>Journal of Biological Chemistry</i> , 2014 , 289, 23367-81	5.4	17
13	Human radiation dosimetry of 6-[18F]FDG predicted from preclinical studies. <i>Medical Physics</i> , 2014 , 41, 031910	4.4	0
12	Impact of quality mentorship on achievements of Shiraz Medical School in the 1970s and the role of Professors Khosrow Nasr and Asghar Rastegar. <i>Archives of Iranian Medicine</i> , 2013 , 16, 251-3	2.4	
11	Combined intensive blood pressure and glycemc control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012 , 81, 586-94	9.9	45
10	Clinical practice. Glycemc management of type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2012 , 366, 1319-27	59.2	117

9	Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. <i>Archives of Iranian Medicine</i> , 2012 , 15, 239-46	2.4	13
8	Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial--clinical implications. <i>Clinical Chemistry</i> , 2011 , 57, 261-3	5.5	6
7	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , 2010 , 376, 419-30	4.0	914
6	Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. <i>Endocrine Practice</i> , 2008 , 14, 639-43	3.2	6
5	Metabolic programming: fetal origins of obesity and metabolic syndrome in the adult. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006 , 291, E439-40	6	47
4	Insulin induces a desensitization of insulin and IGF-1 signaling in INS1-E beta-cells: Mechanisms and consequences on function and survival. <i>FASEB Journal</i> , 2006 , 20, A1170	0.9	
3	Mutations of peripheral myelin protein 22 result in defective trafficking through mechanisms which may be common to diseases involving tetraspan membrane proteins. <i>Biochemistry</i> , 2001 , 40, 9453-9	3.2	64
2	Overexpression of stomatin depresses GLUT-1 glucose transporter activity. <i>American Journal of Physiology - Cell Physiology</i> , 2001 , 280, C1277-83	5.4	86
1	Na,K-ATPase mRNA beta 1 expression in rat myocardium--effect of thyroid status. <i>FEBS Journal</i> , 1999 , 260, 1-8		13